Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Addressing HPV Vaccine Hesitancy by Co-Designing a Digital Health Intervention (HPV-END-IT)

2 juni 2026 uppdaterad av: Sibylle Herzig van Wees, Karolinska Institutet

HPV-Kompassen: a Mixed-Methods Single-Arm Cluster Feasibility Study of a Co-Designed Web-Based Intervention To Strengthen HPV Vaccine Confidence and Uptake in Stockholm, Sweden

This study looks at a digital platform that supports HPV vaccination in schools. The goal is to see if it is useful, easy to use, and practical in real school settings, especially in areas where fewer people get vaccinated.

Researchers will give Year 5 pupils (aged 11-12) and their parents or caregivers access to the platform. It provides clear, trusted information about the HPV vaccine for young people, parents, and school nurses. The aim is to make the vaccine easier to understand and to help answer any questions or concerns.

After using the platform, participants will be asked to share their thoughts.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

100

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Ja

Beskrivning

We will aim to recruit 6-8 compulsory schools in Stockholm County to serve as clusters.

All Year 5 pupils and their caregivers in the study schools are invited.

Inclusion Criteria:

  • The school provides education to pupils in school year 5 and is scheduled to be open throughout the pilot trial period
  • The school is located in an area with HPV vaccine uptake <85.2% (the Stockholm regional average)
  • The head principal and school nurse both consent to participate
  • The school has the capacity to implement the intervention

Exclusion Criteria:

  • Failure to meet the inclusion criteria

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Intervention arm
Participants in the intervention arm receive access to the co-designed, digital platform HPV-Kompassen (eng: The HPV Compass).
Beteende: HPV-Kompassen
HPV-Kompassen is a co-designed, web-based platform that provides tailored and synthesised information with the aim of strengthening confidence in and uptake of the HPV vaccine.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Feasibility of implementation: Acceptability, appropriateness and feasibility of implementation
Tidsram: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.

Measured using Weiner et al.'s implementation outcomes questionnaire (administered to school nurses in participating schools). The questionnaire consists of 12 statements, with four items each assessing the Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM), and the Feasibility of Intervention Measure (FIM).

Respondents rate their level of agreement with each statement using a five-point Likert scale, ranging from "completely disagree" to "completely agree." Responses are coded numerically from 1 to 5, with higher scores indicating stronger agreement. The 12 scores are summed to produce a total scale score ranging from 12 to 60, with higher scores reflecting more positive perceptions of the platform across the three implementation domains.
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
Feasibility of implementation: Acceptability, appropriateness and feasibility of implementation
Tidsram: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
Qualitative data will be collected through semi-structured interviews with school nurses in participating schools. An interview guide developed guided by the Consolidated Framework for Implementation Research (CFIR) will be used to ensure consistency while allowing flexibility to explore individual experiences in depth. The guide includes open-ended questions designed to capture perceptions (see outcome measure 5) and questions related to implementation, e.g., 'How did you experience implementing HPV-Kompassen alongside the regular school health services program?' and 'How well did HPV-Kompassen fit with how schools provide information about HPV vaccination?'.
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
Acceptability of intervention: Intervention delivery strategy
Tidsram: Throughout the intervention period (i.e., months 0-7).
Defined as proportion of adolescents and caregivers that access platform at least once, measured through platform usage metrics.
Throughout the intervention period (i.e., months 0-7).
Acceptability of intervention: Usability of intervention
Tidsram: Immediately after the intervention period (i.e., 'end of treatment') at 7 months.
Usability is measured quantitatively using the Swedish version of the System Usability Scale (SUS). The SUS consists of 10 items assessing perceived usability across key dimensions such as complexity, ease of use, and confidence in using the system. Participants (school nurses, adolescents and caregivers) indicate their agreement with each item on a five-point Likert scale ranging from "strongly disagree" to "strongly agree." Responses are scored according to standard SUS procedures, resulting in a total score ranging from 0 to 100, with higher scores indicating better perceived usability.
Immediately after the intervention period (i.e., 'end of treatment') at 7 months.
Acceptability of intervention: Perceptions of intervention
Tidsram: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
Qualitative data will be collected through semi-structured interviews with participants (school nurses, adolescents and caregivers), focusing on their perceptions of the intervention. An interview guide is used to ensure coverage of key domains while allowing flexibility to explore individual experiences in depth. The guide includes open-ended questions assessing implementation (see outcome measure 2) and perceptions of the intervention, such as "Can you briefly describe your experience of using HPV-Kompassen?" and "Did the information seem credible to you?".
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
Acceptability of intervention: Intervention engagement
Tidsram: Throughout the intervention period (i.e., months 0-7).
Defined as proportion of adolescents and caregivers that actively engage with the platform least once (e.g., visit different modules), measured through platform usage metrics.
Throughout the intervention period (i.e., months 0-7).
Acceptability of intervention: Intervention engagement
Tidsram: End of intervention period (i.e., 'end of treatment') at 7 months.
Qualitative data collection using semi-structured interviews. These interviews aim to understand how, why, and to what extent participants engaged with the platform in practice. Participants (school nurses, adolescents and caregivers) are asked open-ended questions such as "Why did you choose to use the platform?" and "Why did you not use the platform, or use it less than expected?" Additional questions explore when and how the platform was accessed, which features were used, and what factors influenced engagement (e.g., time constraints, relevance of content, or integration with existing workflows).
End of intervention period (i.e., 'end of treatment') at 7 months.
Feasibility of trial protocol: Feasibility of recruitment
Tidsram: From start of school enrollment (i.e., pre-intervention) and throughout the intervention period (i.e., months 0-7).
Measured through study notes, assessing two indicators: proportion of schools that consent to participate and proportion of participants that consent to participate in interviews.
From start of school enrollment (i.e., pre-intervention) and throughout the intervention period (i.e., months 0-7).
Feasibility of trial protocol: Participant retention
Tidsram: From school enrollment (i.e., 'baseline') and throughout the intervention period (i.e., months 0-7).
Measured using study records and platform metrics, assessing two indicators: Proportion of schools retained until study end and proportion of participants using platform who complete the end line survey.
From school enrollment (i.e., 'baseline') and throughout the intervention period (i.e., months 0-7).
Feasibility of trial protocol: Feasibility of data collection methods
Tidsram: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
Measured using study records and survey data, assessing the completeness of data.
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Karolinska Institutet

Utredare

  • Huvudutredare: Sibylle Herzig van Wees, Associate Professor, Karolinska Institutet

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 augusti 2026

Primärt slutförande (Beräknad)

1 juni 2027

Avslutad studie (Beräknad)

1 juni 2027

Studieregistreringsdatum

Först inskickad

27 maj 2026

Först inskickad som uppfyllde QC-kriterierna

2 juni 2026

Första postat (Faktisk)

8 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

8 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 juni 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Andra studie-ID-nummer

  • 2023-00331

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera